Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in Patients With Multiple Sclerosis
NCT07364487Phase 1Withdrawn
- Sponsor
- Huashan Hospital
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in multiple sclerosis (MS), sponsored by Huashan Hospital. Primary endpoints: Dose-Limiting Toxicity Rate at 28 days, Adverse Events Rate at 15 years and 1 more. Planned start Jan 2026; status: withdrawn.
02
Drugs
GC012
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07364487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07364487.